Cargando…
MED12 methylation by CARM1 sensitizes human breast cancer cells to chemotherapy drugs
The RNA polymerase II mediator complex subunit 12 (MED12) is frequently mutated in human cancers, and loss of MED12 has been shown to induce drug resistance through activation of transforming growth factor–β receptor (TGF-βR) signaling. We identified MED12 as a substrate for coactivator-associated a...
Autores principales: | Wang, Lu, Zeng, Hao, Wang, Qiang, Zhao, Zibo, Boyer, Thomas G., Bian, Xiuwu, Xu, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4646802/ https://www.ncbi.nlm.nih.gov/pubmed/26601288 http://dx.doi.org/10.1126/sciadv.1500463 |
Ejemplares similares
-
CARM1 methylates MED12 to regulate its RNA-binding ability
por: Cheng, Donghang, et al.
Publicado: (2018) -
CARM1-mediated methylation of ASXL2 impairs tumor-suppressive function of MLL3/COMPASS
por: Zhao, Zibo, et al.
Publicado: (2022) -
CARM1 automethylation is controlled at the level of alternative splicing
por: Wang, Lu, et al.
Publicado: (2013) -
Differential CARM1 Isoform Expression in Subcellular Compartments and among Malignant and Benign Breast Tumors
por: Shlensky, David, et al.
Publicado: (2015) -
PKM2 methylation by CARM1 activates aerobic glycolysis to promote tumorigenesis
por: Liu, Fabao, et al.
Publicado: (2017)